Cypress Hemp operates in a hemp market where product labels, cannabinoid ratios, testing practices, and legal compliance can matter as much as branding. Founded in 2017, the company sells CBD and THC products across gummies, oils, capsules, topicals, seltzers, and pet formats.
Its current positioning centers on full-spectrum and broad-spectrum hemp formulations, functional ingredients, third-party laboratory testing, and environmental commitments. Rather than concentrating on a single product format, Cypress Hemp has developed a catalog intended to accommodate different preferences and routines.
That approach comes at a time when consumers have access to an increasingly varied selection of hemp-derived products. Differences in cannabinoid content, serving format, additional ingredients, and THC levels can make comparison difficult.
Cypress Hemp addresses that issue partly through product categorization and published laboratory information, giving customers several concrete details to consider before choosing a formulation.
A Founder-Led Background Rooted in Hemp Research
Cypress Hemp says founder Kristy Hebert established the business in 2017 in Louisiana and Virginia after studying Biological and Agricultural Engineering and working across several parts of the hemp industry.
Her professional experience included hemp-grain processing, CBD laboratory testing, and hemp-based construction. The company’s published history also connects that career path with Hebert’s personal experience using CBD while recovering from a serious traffic injury in 2012.
That background helps explain the company’s emphasis on formulation and testing. Cypress Hemp lists business locations in Baton Rouge, Louisiana, and Powhatan, Virginia. Its catalog extends beyond conventional CBD oils to products containing combinations of CBD, THC, CBG, and CBN.
Scientific research provides useful context for this focus on cannabinoid composition. Gianni Barcaccia and colleagues at the University of Padova wrote that “The quality of cannabinoids is strongly dependent on the genotype,” while cannabinoid quantity can also be affected by agronomic practices, environmental conditions, and interactions between genetics and the environment.
Their findings concern cannabis cultivation and breeding rather than Cypress Hemp products specifically. However, they illustrate why cannabinoid composition and reliable information about hemp inputs have become significant considerations throughout the wider industry.
Third-Party Testing Provides More Product Information
One of Cypress Hemp’s more concrete customer-facing practices is publishing batch-specific laboratory documentation. The company provides Certificates of Analysis for products and says these reports cover cannabinoid potency as well as testing for heavy metals, microbes, pesticides, and residual solvents. Its laboratory information identifies testing providers with ISO 17025:2017 certifications.
For customers, this documentation offers another way to examine what a particular product contains. It also helps distinguish measurable product characteristics from general wellness language, which is particularly relevant in a market where product formulas and cannabinoid concentrations can differ considerably.
Cypress Hemp also provides regulatory disclaimers. The efficacy of its products has not been confirmed by FDA-approved research, and its products are not intended to diagnose, treat, cure, or prevent disease. It advises customers to speak with healthcare professionals about potential interactions or complications.
Cannabis genetics research adds context to this emphasis on measurement. Reporting on research by cannabis geneticist Jonathan Page and colleagues noted: “With genetic markers linked to desirable traits such as THC content, plant breeders can use DNA analyses to screen seedlings for sought-after properties instead of waiting months for the plants to mature into adults.”
Barcaccia and colleagues similarly wrote that modern breeding methods require multidisciplinary skills and tools for evaluating or predicting molecular genotypes and biochemical profiles.
These findings relate to breeding rather than finished consumer goods, but they demonstrate the importance of measurable cannabinoid characteristics before hemp reaches the manufacturing stage.
Full-Spectrum Gummies Offer Clearly Defined Formulations
Cypress Hemp’s gummy range illustrates how the company translates hemp extracts into products intended for different routines. Its Everyday CBD Gummies contain 900 mg of CBD in a 30-count package, providing 30 mg per gummy. The full-spectrum formulation also contains ashwagandha, lion’s mane, and L-theanine.
The company states that its full-spectrum products contain naturally occurring THC and warns that consuming THC-containing products can lead to a positive drug test. That disclosure is important for customers whose employment, sporting activities, or other circumstances require drug screening.
Other formulations extend the range beyond standard CBD gummies. Cypress Hemp sells Sleep CBD + CBN Gummies and Energy CBD + CBG Gummies. The sleep formulation pairs cannabinoids with ingredients including chamomile, reishi mushroom, and L-theanine. Its energy product uses a different cannabinoid and ingredient profile.
This segmentation gives customers a straightforward way to compare cannabinoid combinations and supporting ingredients. The cypresshemp CBD gummies page provides product-level information about the company’s approach to full-spectrum formulations, including serving information, ingredients, cannabinoid content, and THC disclosures.
Multiple Formats Address Different Customer Preferences
Cypress Hemp does not restrict its catalog to gummies. Its CBD range includes oils, softgels, topical products, and cannabinoid-ratio edibles. Its full-spectrum collection similarly covers CBD oils, muscle and joint products, pet oil, CBN sleep oils, and softgels.
This variety gives customers a choice between ingestible and topical formats as well as full- and broad-spectrum extracts. Full-spectrum products retain CBD alongside other naturally occurring hemp compounds and trace amounts of THC. Broad-spectrum formulations, meanwhile, are intended to provide multiple hemp compounds without THC.
The distinction matters for people paying close attention to THC exposure. Cypress Hemp notes that state regulations can vary even when a hemp product complies with federal requirements. It therefore advises customers to check applicable local rules.
Sustainability Adds Another Element to the Brand
Cypress Hemp also connects its business model with environmental initiatives. The company says it contributes toward planting one tree for every product purchased. It has also reported using biodegradable boxes, compostable cushioning, and carbon offsets as part of its packaging and sustainability practices.
Its stated mission connects the American hemp industry with human well-being and environmental regeneration. These commitments broaden the company’s positioning beyond cannabinoid formulations alone, although customers can assess them separately from product quality and laboratory results.
Final Thoughts
Overall, Cypress Hemp’s position rests on several identifiable elements: a diversified cannabinoid catalog, batch-specific laboratory documentation, full- and broad-spectrum choices, specialized gummy formulations, regulatory disclosures, and stated environmental commitments.
For customers assessing hemp products, the most concrete information is the material they can examine directly. Ingredient lists, cannabinoid quantities, Certificates of Analysis, THC warnings, serving information, and legal disclosures provide practical points of comparison.
In an industry where broad wellness claims can exceed the available clinical evidence, Cypress Hemp’s published product data gives customers a more specific basis for understanding what its formulations contain and how the company approaches the hemp market.
